Daily Archives: April 27, 2021

A biotech company that has spent 11 years researching supplements to increase human longevity plans to launch its supplements later this year. Longevica says it has attracted a total of $13 million from investors, including Alexander Chikunov, a longevity investor, who is also president of the company.

Longevica says it created a biotechnology platform for longevity after researching the life-span of laboratory mice. It now aims to produce medicines, dietary supplements and food products.

The longevity space is a growing sector for tech startups. Google backed the launch of Calico in the space. Late last year Humanity Inc. raised $2.5 million in a round led by Boston fund One Way Ventures for its longevity company that will leverage AI to maximize peoples health span.

Longevicas CEO Ainar Abdrakhmanov, backing up his companys aim to tap the desire for people to live longer, said: According to the WHO, by 2050, 2 billion people will be 60+ years old. By 2026, the sales of services and products for this audience will be around $27 trillion By comparison, it was only $17 trillion in 2019.

According to CB Insights, life-extension startups raised a record total of $800 million in 2018 alone. And there are some high-profile investors in the space.

PayPal co-founder Peter Thiel invested in Unity Biotechnology, which is developing drugs to treat diseases that accompany aging. And Ethereum founder Vitalik Buterin invested $2.4 million worth of Ether into the nonprofit SENS Research foundation, where famed longevity research Aubrey de Grey is chief science officer, to develop rejuvenation biotechnologies.

Longevica is basing its platform on the work of scientist Alexey Ryazanov, who holds 10 U.S. patents in the space, and is a longtime researcher into the regulation of protein biosynthesis cells.

Chikunov said: I gathered scientists known in this field to discuss their approaches to the problem. Then Alexey Ryazanov proposed the innovative idea of large-scale screening of all known pharmacological substances on long-lived mice in order to find those that prolong life.

Under the leadership of Ryazanov, Longevica says it used 20,000 long-lived female mice and 1,033 drugs representing compounds from 62 pharmacological classes to find five substances that statistically significantly increased longevity by 16-22%: Inulin, Pentetic Acid, Clofibrate, Proscillaridin A, D-Valine.

From this work, they formed a view about the elimination of certain heavy metals from the body and improved the bodys ability to remove toxins.

The rest is here:
Longevity startup Longevica plans to launch supplements based on long-term research - TechCrunch

DUBLIN--(BUSINESS WIRE)--The "Precision Medicine Software - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Amid the COVID-19 crisis, the global market for Precision Medicine Software estimated at US$1.3 Billion in the year 2020, is projected to reach a revised size of US$2.6 Billion by 2027, growing at a CAGR of 10.1% over the period 2020-2027.

On-Premise, one of the segments analyzed in the report, is projected to record 9.4% CAGR and reach US$1.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Cloud segment is readjusted to a revised 11.1% CAGR for the next 7-year period.

The U.S. Market is Estimated at $352.1 Million, While China is Forecast to Grow at 13.4% CAGR

The Precision Medicine Software market in the U.S. is estimated at US$352.1 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$537.8 Million by the year 2027 trailing a CAGR of 13.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7% and 8.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR.

Select Competitors (Total 34 Featured):

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/hspilq

View post:
Outlook on the Precision Medicine Software Global Market to 2027 - Featuring Fabric Genomics, Foundation Medicine and Human Longevity Among Others -...

Of all the pleasures of human life, sex is arguably the most pleasurable. Though sex is a vehicle for procreation, the human can experience it well past the procreation age. It has long been recognised that diabetes, hypertension and abnormal blood fats are associated with less of an ability to have sex, often leading to erectile dysfunction in men. It has been well documented that a malfunctioning of the internal lining of the hearts arteries, is a major consideration in heart disease. It therefore follows that such a malfunction of the internal lining of the artery to the penis may also be responsible for erectile dysfunction. It is no wonder that many authorities suggest that erectile dysfunction may be a surrogate marker of heart disease.The question then arises - are there any health benefits to sex? Sexual intercourse and not masturbation lowers systolic blood pressure, and the lowering of blood pressure has several health benefits, as reported in the journal Biological Sexology. The partner who also enjoyed sex had lower diastolic blood pressure. Women who are hugged more often, tend to have lower blood pressure. Having sex once or twice a week reduces the risk of fatal heart attack by half, when compared with men who had sex less than once a month. Frequent sex also helps to improve ones immunity. Sex once or twice a week is associated with higher levels of immunoglobulin A, which helps against infections and colds, as compared to those who are abstinent or have sex less than once a week. Strangely, those having sex three or more times a week did not show an increased level of immunoglobulin.

More:
The many physical and mental health benefits of sex - Times of India

Serimmune CEO Noah Nasser and CTO John Shon discussed the capabilities of the immune intelligence startup intended to aid in the development of diagnostics, vaccines, and therapeutics.

What is Serimmune?

Serimmune is an immune intelligence company devoted to placing the power and complexity of personal antibody response in the hands of consumers, patients, clinicians and researchers. Serimmunes proprietary technology identifies and exploits the universe of relationships between antibodies and antigens. The companys proprietary technology, Serum Epitope Repertoire Analysis (SERA), provides a holistic view of an individuals functional antibody repertoire, to identify the diverse immunogenic factors in health and disease.

The companys platform combines a novel, random bacterial display peptide library with next generation sequencing, machine learning, and custom bioinformatics to reveal the many diverse antigens stimulating immunity. Serimmunes Human Immunity Map is a growing database of immune interactions that can be interrogated to inform the development of multiplex diagnostics, vaccines and therapeutics.

Why did you join this company?

Noah Nasser

Noah: Ive been in biotech, specifically in diagnostics, for over 25 years, gravitating towards companies and technologies that I felt could transform healthcare. Opportunities to work on transformational technologies and services are rare. I am driven to improve diagnostic medicine across the board. By commercializing Serimmunes technology and bringing it to market in a meaningful way, we have an opportunity to change the very nature of diagnostic medicine and to radically advance immune research.

John: I am trained in medicine, but I have always been intensely engaged with data. Ive worked at large and small companies focused on data-driven technologies leveraging machine learning and AI, that have the ability to change our understanding of disease and thereby change the way we diagnose and treat disease. Immunology had always seemed to be a complicated field that needed a data-driven approach. Serimmune has the technology to measure all the proteins that the human immune system is responding to by using only a small amount of blood. The opportunity to create large databases and bring genomics and immunology together in a way that had never been done before is exciting.

What specific need/problem are you seeking to address in healthcare?

Noah: Critical information about human health resides in the functional antibody repertoirethe complete suite of antibodies that circulate within the bodybut tools to interrogate this information have been inadequate to date. Serimmune was founded to meet this need. The human immune system is the best naturally occurring diagnostic and potential therapeutic tool in existence. If we can access information in the functional antibody repertoire with superior tools and scale, it would open up a world of knowledge about patient health.Deep immunome information has incredible value to patients who are concerned about their immunity or health status. This is the real value of Serimmune and our technology. Giving everyone the ability to understand their personal immune response to live healthier lives is central to Serimmunes vision. Ultimately, leveraging the functional antibody repertoire will transform healthcare.

What does your product do? How does it work?:

Noah: The backbone of Serimmunes technology is a massive random, bacterial peptide display library. Starting with less than 50 microliters of sample, we bind circulating antibodies to the peptide library. The bound peptide sequences are then sequenced and the data analyzed with our proprietary algorithms which leverage cloud computing and advanced machine learning. Through this analysis, we translate patterns of peptides to conserved motif panels and from motifs to epitopes, epitopes to proteins and proteomes. Using our database, we can link immune epitope patterns to individual disease and across disease states. Because the library is random and not dependent on a specific target proteome, we can connect these patterns without an a priori diagnostic thesis and so can identify signals from oncology, autoimmune and infectious targets in the same sample in a single workflow.

Long term, much of our value lies in Serimmunes database which contains the disease, demographic and other patient information as well as the generated epitope-level data. As our database grows with each new cohort of samples, so does our overall ability to draw conclusions from epitope level data in individual disease states, across diseases or across diverse sets of symptoms. These data linkages are a key component of our long-term strategy and value. Archived data is automatically updated each time new associations between epitopes and disease are made. This may help identify individuals who share a common disease signature in their immune profile.

John Shon

John: As Noah mentioned, the technology is based on a 10 billion random peptide library with which we can use to look for anything and everything that could impact someones immune healththe viruses weve fought, response to the medications weve taken, and environmental exposures. The real insights emerge once we have a baseline of a persons immune map and then compare it to that of thousands of other people in the Serimmune database. Thats where diseases like cancer antigens or markers of an autoimmune disease can be revealed. We are working on methods where we can start with a known proteome and find epitopes and antigens that are significant for that proteome because we have that large database with multiple and diverse cohorts.

Is this your first healthcare startup? Whats your background in healthcare?

Noah: I have been in healthcare for more than 25 years. I spent the first half of my career at Quidel, an immunodiagnostics company in San Diego. I began as a lab technician and eventually transitioned into sales, marketing and leadership roles with the company. Quidel was incredibly entrepreneurial and allowed me an opportunity to to grow and learn rapidly.

In 2011, I joined Verinata, one of the first companies to commercialize non-invasive prenatal screening based on cell-free DNA technology. It was my first experience leading the commercialization of a truly transformational product and an incredible opportunity to prove the value of disruptive healthcare technology.

The team at Verinata was really great;I learned so much from them about leadership, teamwork and the challenges in commercializing novel technologies in our current healthcare landscape.

After Verinata was acquired by Illumina, I spent time in a few other startups in commercial leadership roles before joining Counsyl, where I worked on transformational systems designed to apply what we knew about reimbursement, work flows and detection technologies to improve both physician and patient experiences. Counsyl gave me a true appreciation for the importance of systems and workflows in bringing technology to market in healthcare.

Prior to joining Serimmune, I was Chief Commercial Officer at Human Longevity, where I gained meaningful consumer experience as well.

John: After completing my residency in internal medicine, I completed a post-doctoral fellowship in biomedical informatics at Stanford. I went on to work in a number of large and small companies where the emphasis has really been on developing large translational medicine data stores and applying computational methods to high-throughput genetics, genomics, cheminformatics, and clinical data for drug discovery and development. I worked for a decade at Roche and Johnson & Johnson as a VP leading transformational informatics teams, and then spent several years as a VP at Illumina to help refine their population-scale sequencing, variant calling and variant interpretation platforms for rare disease and cancer. The team I built there also made great strides in applying deep learning to large cohorts to predict pathogenic variants and splice site variants at the individual level.

Serimmune attracted me because of the unique opportunity to bring genomics and machine learning to immunology at scale with a high throughput, robust assay that has clinical-grade performance.

Who is your customer? How do you generate revenue?

Noah: Today, we apply our technology exclusively in research markets, partnering with pharmaceutical companies and academic researchers to better describe antibody antigen interactions in specific diseases. Many of these projects are bespoke collaborations. Most recently, we have launched a standardized COVID-19 specific application for our technology which we believe will accelerate therapeutic and vaccine development particularly with new variants being described.

We have been evaluating various strategies for commercializing our platform in clinical care. As we have formalized our go-to-market strategy in the clinical space, we recognized the challenges our technology presents to current care paradigms. Todays diagnostics market operates in a very linear fashion: a single test, a single CPT code, a set of diagnostic criteria and hopefully an answer. This can lead to excessively long diagnostic odysseys for patients with diverse symptoms or complex disease.

With Serimmunes unbiased and random library approach technology, we have the potential to test a universal set of targets based on symptoms without a prior diagnostic thesis and proceed to the root cause very quickly. In other words, because we use a random library and an unbiased approach, we are getting information without having to say, I think you have X disease and I will test you just for that. This is simply not how physicians are used to prescribing care or how laboratories are reimbursed for it.

We see two key trends in our market. First as a consequence of the ongoing pandemic, we have seen an elevated focus on the importance of immunity at the patient and consumer level. Secondly, individuals are playing a more significant role in their care and are paying more attention to laboratory diagnostic tests to assist in living healthier lives. Through our preliminary market research we have demonstrated that Serimmunes technology may appeal directly to consumers who have concerns about their immune system, like those with an autoimmune disease, Lyme Disease, or chronic fatigue syndrome just to name a few. These are people who are engaged in their own healthcare and have an ongoing interest in their immune status. Of course this hinges on our ability to provide relevant, high value, clinically-actionable information in an easy to understand digital format.

John: Using Serimmunes technology, we can look at many factors in immunity at one time and monitor appropriate responses longitudinally. We can understand how the immunome changes over time, for example in response to vaccines or treatments, and we can also compare an individuals immune response to that of other individuals in our database with similar conditions. Putting this information into context will be critical for individuals as they try to understand their health.One of the most profound uses for our technology is determining whether a person is suffering from fatigue or joint pain where tick-borne disease is a key differential diagnostic consideration. We have one of the best platforms for assessing the antibody response to tick-borne pathogens. Serimmunes technology will also benefit customers who are concerned about autoimmune disease, myalgic encephalitis / chronic fatigue syndrome, or even COVID long hauler syndrome, and want to support research into how their immune response changes over time.

Do you have clinical validation for your product?

Noah: Scientists at Serimmune have published a number of papers documenting the performance of our technology in specific applications like tick-borne diseases, COVID-19, neglected tropical diseases and even cancer. We hope to publish many more in the near future further validating our clinical efficacy and performance.

So far, in a research environment, we have validated performance for more than 50 targets spanning infectious and autoimmune disease as well as oncology, with more being added. In the coming year, we are planning the launch of our CLIA lab. We will use a consumer-initiated physician directed model, with clinical staff that help facilitate testing and put results into context to help patients understand their information.

The future is exciting. Our researchers are working with partners around the world to validate our signals on orthogonal platforms, potentially to port our technology onto near patient platforms for underserved markets. Additionally, discoveries from our database may prove important to pharmaceutical partners as biomarkers of response or therapeutic candidates.

John: SERA is special in that we have demonstrated in multiple conditions that we can achieve clinical-grade performance with a high-throughput assay. With a data-driven approach, we have repeatedly identified antigens and epitopes that have previously been described in the literature that have clinical relevance. One of the ultimate long-term benefits that were seeing with this database is with clinical disease associations. For example, in a data-driven way, we find that multiple infections are associated with each other, confirming known geographic epidemiology or confirming known sharing of infectious disease vectors. Serimmune has the potential to really disrupt and change medicine, not only because of the clinical applications but because of the discoveries that were going to make about disease associations in populations, between infectious disease, autoimmune disease, and cancer, where the humoral immune system is central to disease understanding.

At what stage of development is your lead product?

Pre-clinical

Photo: Peshkova, Getty Images

Continue reading here:
Serimmune CEO: Leveraging the functional antibody repertoire will transform healthcare - MedCity News

Are you experiencing anxiety about Tax Day? asks Rachel Rohaidy, M.D., referring to the upcoming May 17th IRS deadline for filing your taxes. Dr. Rohaidy, a board certified psychiatrist at Baptist Health Primary Care and medical director of The Recovery Village at Baptist Health, says that what youre actually feeling is the anxiety that comes from fear of the unknown and the inability to be resilient in your reactions.

As a psychiatrist, Dr. Rohaidy believes in the practice of positive psychiatry and positive psychology to enable patients to develop the skills they need to cope with anxiety, alleviate suffering and increase their wellbeing.

Positive psychiatry believes people can learn to control response to stress by practicing mindfulness, Dr. Rohaidy says. One of the easiest ways to practice mindfulness is to sit with your emotions and recognize them. Feelings of anger, sadness and frustration that increase stress can actually be reduced over time.

When helping patients learn how to get through stressful times, whether its preparing and paying ones taxes or dealing with a difficult situation at home or work, Dr. Rohaidy says she likes to emphasize three important elements of positive psychiatry and positive psychology: resilience, optimism and social engagement.

According to Dr. Rohaidy, the job of a mental health professional is incomplete if all they focus on is the problem by just prescribing medicine. Medication, she cautions, is not the answer for everyone.

Resilience and social engagement are better treatment options, notes Dr. Rohaidy, who says that using positive psychiatry and positive psychology everyday can help you not only with your emotional wellbeing but can help you maintain good health as well.

Theyve also been proven to lead to greater longevity and improved outcomes when coping with illnesses such as cancer or chronic conditions like rheumatoid and psoriatic arthritis, hypertension, diabetes and cardiovascular disease, she says.

Being resilient is the capacity to respond to adversity in a healthy way, says Dr. Rohaidy. More than just responding to setbacks, its a mindset that can be used to develop mental flexibility and optimism, which she says are essential components of resilience.

Studies show the impact of creating a healthy mindset, Dr. Rohaidy adds. Over time, this practice lowers depression, reduces suicides and helps in the reduction of substance abuse in people involved in trauma.

Dr. Rohaidy identifies the essentials of resilience, which include:

Being positive takes work, according to Dr. Rohaidy, and its something you have to work on every single day. Become more self-aware and think about how you process things, she says. Be willing to learn new tasks on the road to becoming more resilient.

So, if Tax Day or some other situation in your life is weighing heavily on you, think positively. Instead of dreading having to file your taxes or worrying about how much you owe this year, be thankful you have a steady job that provides taxable income, Dr. Rohaidy says. Not everyone can say that.

Tags: Baptist Health Primary Care, Rachel V.F. Rohaidy M.D., resilience, Stress, Tax Day, The Recovery Village at Baptist Health

Continued here:
Ask the Psychiatrist: Is Tax Day the Only Thing That's Causing You Stress? - Baptist Health South Florida

This is the time to look at a world redesign beyond the narrow national interests of America or China, one which would serve the best interests of the planet and the people. The future is not only about national pride, business, markets, religion or race, with the bogey of an enemy at the border; it is about climate change and human development.

Now is the time to move from violence and military options to non-violence and the imperative of peace. This will require collaboration, as opposed to confrontation and competition. It may be all right to compete in certain areas. Still, it is more important to cooperate on strategic issues related to the planet and the people of the world. Here, political leadership matters. Suppose world leaders do not come together at this crucial moment. In that case, we will indeed be riding a path to permanent destruction.

Global leaders need to recognise that the future belongs to globalists and not nationalists. It is not about an international liberal order, but global peace and prosperity for all. It is about empowering every human being to explore and experience life and nature in their own way, with freedom and flexibility. This will require respect, sharing, caring and teamwork among world leaders. It will demand a functional and friendly relationship between world powers.

The redesign of democracy, capitalism, environment and institutions is not going to be simple. It will require a deeper understanding and appreciation of human values and our character, and addressing climate change issues with the spirit of sacrifice and long-term perspectives. It will also need the collaboration of communist leaders from China and Russia, monarchs from the Middle East, and others.

We essentially need a third vision of the world that transcends national interests and takes into account global issues, from trade to environmental impacts. We need a vision that values human capital more than financial capital. A vision that works for everyone to attain a multipolar world, where people at the bottom of the economic pyramid benefit the most.

We need to ask the worlds people: Do they want to live forever with poverty and hunger, with inequality and unemployment, under the shadow of discrimination and fear, with the police at every corner and the military at all borders? Or do they want to live in peace with friendly neighbours, in a clean environment, and with respect, dignity, equality, opportunities and hope for all? The present reality is scary. Dont we want to change it?

We want to reset international interests over national interests, human diversity over human differences, globalism over nationalism, inclusion over exclusion, non-violence over violence, rationality over religion, and respect over race. We want international cooperation on climate change, global health, poverty, hunger, violence, security, amity with neighbours and much more.

I firmly believe that it is possible to redesign the world with this third vision because multiple, intricate and timely technologies with incredible innovations in information, genetics, bio, nano and material sciences are now all coming together. They are taking deep roots across the social, political and economic landscape, which will profoundly impact our livelihood and longevity. T

his will give new meaning to life, work, values, wisdom and progress. It will lead to a new development model based on cooperation, collaboration and communication, which can finally deliver peace, justice and prosperity to all by the middle of this century.

We are so used to thinking and behaving traditionally with our narrow compartmentalisation of people and their ideas, values and experiences. We always tend to look at past experiences and our history to find solutions. We find pleasure in the past, comfort in the present, and fear for the future.

The future is prosperous with new bold ideas and different toolkits, such as hyperconnectivity, which did not exist earlier. The future demands a new mindset with creativity, innovation and courage. I firmly believe that we are at a crossroads because of hyperconnectivity.

Recently, a bright young friend of mine showed me a new dimension to global power and conflicts with a different perspective to what I had visualised. He opened my eyes to religions essential role in societys organisational architecture and its associated conflicts and wars. There are basically four significant religions globally which mobilise the masses and organise power: Christianity, Islam, Hinduism and Buddhism.

All significant conflicts, wars and invasions have been carried out predominantly by the big powers like the Romans, Ottoman, Moguls, British Empire, etc, to expand power, influence, control and wealth. He argued that the concept of time for Christianity and Islam is absolute: you live, and you die.

On the other hand, the concept of time for Hinduism and Buddhism is infinite: you continue through rebirth for another cycle. He feels this may have something to do with the idea of accumulating wealth and power in one lifetime. He also pointed out that the wars in Pearl Harbour, Korea and Vietnam were rare wars between Christianity and Buddhism. The ongoing conflicts in Syria, Afghanistan, Iraq, Libya and others are wars between Christianity and Islam. 9/11 may be considered a blow by Islam against the only superpower in the world.

To me, that made a lot of sense. In my heart, I am Hindu, Muslim, Christian, Jew, Buddhist, Sikh, Jain, atheist and a lot more. To me, all religions inculcate fundamental human values and promote goodness in people. Perhaps it is obvious, but when you put these things in perspective, it is clear that the challenge going forward will be to build bridges with all religious organisations and associated power centres, provided they have genuine respect for each other with a commitment to peace, prosperity and non-violence. Only by doing this can we together take humanity to the next level.

Bold and brave ideas are essential for driving our new world vision now. Unfortunately, we have always looked for solutions in the economy and the market, technology, military or ideology we have never explored humanism in our quest for solutions.

First, we must understand, appreciate and internalise the simple fact that our planet is a unique interconnected and integrated system where soil and sand, birds and insects, animals and people are all interdependent. We live off the same system of air, water, flowers and forests. Peace, the economy, the environment and health issues are also interconnected and interrelated. The key is to strive for unity with respect, equality and equity for all living systems.

We have to ask what belongs to whom on our planet. Who owns the Amazon forests? Do they belong to Brazil or to the world? Should we all not be concerned about what happens to the Amazon? Our rivers? Our oceans? What affects one affects all of us. What happens to Africa in the next twenty-five years will affect America, China, India and the entire world. We need to think from the viewpoint of biology, life and dynamic assets, and not merely markets or material and static assets.

We must remember that the concept of modern states and national borders began only recently. We may live within boundaries and borders, but we must think beyond them with an eye out for humanity at large. The best way to understand what is right for society, the world and the future is to ask young people what they want. They will tell you that they wish to have love, a clean environment, home, education, health, family, friends and fun. They do not want violence, war, power or riches. The answers are simple. We make it complicated.

Excerpted with permission from Redesign the World: A Global Call to Action, Sam Pitroda, Penguin Business.

Go here to read the rest:
Sam Pitrodas new book argues for resetting the world and then designing it afresh - Scroll.in

A SWOT Analysis ofLongevity and Anti-senescence Therapy, Professional Survey Report Including Top Most Global Players Analysis with CAGR and Stock Market Up and Down.

The market report, titled Longevity and Anti-senescence Therapy Market, is a broad research dependent on Longevity and Anti-senescence Therapy market, which examines the escalated structure of the present market all around the world. Planned by the sufficient orderly system, for example, SWOT investigation, the Longevity and Anti-senescence Therapy market report demonstrates an aggregate appraisal of overall Longevity and Anti-senescence Therapy market alongside the noteworthy playersAcorda Therapeutics, Unity Biotechnology, Antoxerene, Celgene, Cohbar, Senex Biotechnology, Human Longevity Inc., T.A. Sciences, Agex Therapeutics, Recursion Pharmaceuticals, Calico Life Sciences, Spotlight Bioscience, Powervision Inc., Sierra Sciences Llc, Restorbio, Insilico Medicine, Oisin Biotechnology, Senolytic Therapeutics, Proteostasis Therapeutics Inc., Prana Biotechnology Ltd., Cleara Biotechof the market.

Apply here for the FREEsample copy of the report @:https://www.marketresearchstore.com/sample/longevity-and-anti-senescence-therapy-market-819933

The conjecture for CAGR (Compound Annual Growth Rate) is expressed by the Longevity and Anti-senescence Therapy Market report in the terms of proportion for the particular time length. This will likewise assist the client with understanding and settle on an exact decision based on an expected diagram. Furthermore, The report presents a detailed segmentationSenolytic Drug Therapy, Gene Therapy, Immunotherapy, Others, Market Trend by ApplicationLongevity, Senescence Inhibition, Cardiovascular Diseases, Neural Degenerative Diseases, Ophthalmology Disorders, Cancerof the global market based on technology, product type, application, and various processes and systems.

Income age and assembling scale are the two superior divisions on which the Longevity and Anti-senescence Therapy market is reliant. An evaluation of the markets fundamental segment and the geological territories around the globe is additionally canvassed in this report. Different Longevity and Anti-senescence Therapy market factors, for example, development, confinements, and the arranged attributes of each point have been accounted profoundly. Based on this qualities, the Longevity and Anti-senescence Therapy market report predicts the fate of the market all around.

The additional geographical segments are also mentioned in the empirical report.

North America:U.S., Canada, Rest of North AmericaEurope:UK, Germany, France, Italy, Spain, Rest of EuropeAsia Pacific:China, Japan, India, Southeast Asia, North Korea, South Korea, Rest of Asia PacificLatin America:Brazil, Argentina, Rest of Latin AmericaMiddle East and Africa:GCC Countries, South Africa, Rest of Middle East & Africa

The production and distribution up-scales and downscales along with the market share can enlighten the readers with the overall market growth and development. The entire colossal of fine points scripted in the report provides the entire gist of the report that signifies the market expansion and sales volume or value.

Read Detailed Index of full Research Study at::https://www.marketresearchstore.com/market-insights/longevity-and-anti-senescence-therapy-market-819933

This report holds every last part of the global market for this particular area, going from the essential market information to numerous critical criteria, according to which the Longevity and Anti-senescence Therapy market is institutionalized. The principle working areas of the Longevity and Anti-senescence Therapy market are additionally secured dependent on their execution. The Longevity and Anti-senescence Therapy market report covers research of present strategies, directions, and market chain. Considering different variables like merchandise, their chain of generation, chief producers, and supply & order, value, for business is composed in this report.

The report likewise contains as far as possible, attributes of interest and supply, pinpoint examination, and the consecutive introduction of the Longevity and Anti-senescence Therapy market around the world.

Impact Of COVID-19

The most recent report includes extensive coverage of the significant impact of the COVID-19 pandemic on the Heated Jacket division. The coronavirus epidemic is having an enormous impact on the global economic landscape and thus on this special line of business. Therefore, the report offers the reader a clear concept of the current scenario of this line of business and estimates the aftermath of COVID-19.

Chapter 1, Definition, Specifications and Classification of Longevity and Anti-senescence Therapy, Applications of Longevity and Anti-senescence Therapy, Market Segment by Regions;Chapter 2,Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3,Technical Data and Manufacturing Plants Analysis of Longevity and Anti-senescence Therapy, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4,Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Longevity and Anti-senescence Therapy Segment Market Analysis (by Type);Chapter 7 and 8, The Longevity and Anti-senescence Therapy Segment Market Analysis (by Application) Major Manufacturers Analysis of Longevity and Anti-senescence Therapy ;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Senolytic Drug Therapy, Gene Therapy, Immunotherapy, Others, Market Trend by Application Longevity, Senescence Inhibition, Cardiovascular Diseases, Neural Degenerative Diseases, Ophthalmology Disorders, Cancer;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, The Consumers Analysis of Global Longevity and Anti-senescence Therapy ;Chapter 12, Longevity and Anti-senescence Therapy Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, Longevity and Anti-senescence Therapy sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquire Here Get customization & check discount for report @:https://www.marketresearchstore.com/inquiry/longevity-and-anti-senescence-therapy-market-819933

Reasons for Buying Longevity and Anti-senescence Therapy market

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Market Research Store

At Market Research Store, we provide reports about a range of industries such as healthcare & pharma, automotive, IT, insurance, security, packaging, electronics & semiconductors, medical devices, food & beverage, software & services, manufacturing & construction, defense aerospace, agriculture, consumer goods & retailing, and so on. Every aspect of the market is covered in the report along with its regional data. Market Research Store committed to the requirements of our clients, offering tailored solutions best suitable for strategy development and execution to get substantial results. Above this, we will be available for our clients 247.

Ask Queries/Buy Report Directly by Contacting Us@[emailprotected]

Contact US:

Market Research Store3422 SW 15 Street,Suit #8138,Deerfield Beach,Florida 33442, USATel: +1-386-310-3803GMTTel: +49-322 210 92714Website:https://www.marketresearchstore.com

https://neighborwebsj.com/

Visit link:
Global Longevity and Anti-senescence Therapy Market Research Report Covers, Future Trends, Past, Present Data and Deep Analysis 2020-2026 ...